Medicinova (MNOV) Return on Capital Employed (2011 - 2026)
Medicinova (MNOV) posted quarterly Return on Capital Employed of 31.04% for Q4 2025, down 758.0% year-over-year from 4.72% in Q4 2024, and down 5.28% quarter-over-quarter from 29.48% in Q3 2025.
Medicinova (MNOV) Return on Capital Employed (2011 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Return on Capital Employed for 15 consecutive years, with 31.04% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 758.0% year-over-year to 31.04%; the TTM figure through Dec 2025 stood at 31.04% (down 758.0% YoY), while the FY2025 annual figure was 28.3%, down 649.0% from the prior year.
- Return on Capital Employed slipped to 31.04% in Q4 2025 per MNOV's latest filing, from 29.48% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.79% in Q4 2021 and bottomed at 31.04% in Q4 2025.
- Historically, Return on Capital Employed has averaged 19.15% across 5 years, with a median of 17.34% in 2022.
- Annual changes were most pronounced in 2021 — Return on Capital Employed soared 733 bps — and 2025, when it slumped 1084 bps.
- Medicinova's Return on Capital Employed stood at 11.79% in 2021, then sank by 70 bps to 20.02% in 2022, then increased by 23 bps to 15.49% in 2023, then plunged by 51 bps to 23.46% in 2024, then tumbled by 32 bps to 31.04% in 2025.
- Business Quant data shows MNOV's Return on Capital Employed at 31.04% in Q4 2025, 29.48% in Q3 2025, and 27.44% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 | -31.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.51% |
| Dec 31, 2025 | -31.04% |
| Sep 30, 2025 | -29.48% |
| Jun 30, 2025 | -27.44% |
| Mar 31, 2025 | -24.49% |
| Dec 31, 2024 | -23.46% |
| Sep 30, 2024 | -21.14% |
| Jun 30, 2024 | -16.60% |
| Mar 31, 2024 | -16.23% |
| Dec 31, 2023 | -15.49% |
| Sep 30, 2023 | -16.22% |
| Jun 30, 2023 | -19.96% |
| Mar 31, 2023 | -20.28% |
| Dec 31, 2022 | -20.02% |
| Sep 30, 2022 | -17.93% |
| Jun 30, 2022 | -16.74% |
| Mar 31, 2022 | -16.21% |
| Dec 31, 2021 | -11.79% |
| Sep 30, 2021 | -12.58% |
| Jun 30, 2021 | -12.18% |